Target intelligence / Profile preview

Serotonin receptor 2A (5-HT2A) and Serotonin receptor 2C (5-HT2C) (5-HT2A and 5-HT2C)

Target
5-HT2A and 5-HT2C
Molecular classification
G protein-coupled receptor (GPCR), Receptor
01

Overview

Serotonin receptor 2A (5-HT2A) and serotonin receptor 2C (5-HT2C) are closely related G protein-coupled receptors (GPCRs) that bind the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) and couple primarily to the Gq/11 signaling cascade, resulting in excitatory neurotransmission and complex intracellular signaling. 5-HT2A is extensively distributed in the cortex, hippocampus, cardiovascular system, platelets, and other tissues, and plays key roles in cognition, perception, vascular tone, and the pharmacological effects of both psychedelic and antipsychotic drugs. 5-HT2C is primarily found in the central nervous system, especially the choroid plexus and areas regulating mood and appetite, with known involvement in psychiatric disorders, obesity, and unique patterns of genetic regulation such as X-linked inheritance and RNA editing[1][2][3][4][5][6][7]. These receptors are major therapeutic targets for antipsychotics, antidepressants, weight-loss agents, and hallucinogenic compounds, and are research foci in neuropsychiatric, metabolic, and cardiovascular diseases. Biochemically, they can form homo- and hetero-dimeric or higher-order complexes and influence diverse behavioral and physiological processes through widespread central and peripheral actions.

Other names
5-HT2A receptorHTR2ASerotonin receptor 2A5-HT2C receptorHTR2CSerotonin receptor 2CSerotonin 2A receptorSerotonin 2C receptor5-hydroxytryptamine receptor 2A5-hydroxytryptamine receptor 2C
02

Mechanism of action

Agonists at 5-HT2A/2C stimulate Gq/11-coupled signaling, increasing IP3/DAG and intracellular calcium signaling[1][7] Antagonists inhibit receptor-mediated neurotransmission and associated downstream effects[5][7] Psychedelics act primarily as 5-HT2A partial agonists to induce altered perception and cognition[1][5][7] Antipsychotics often act as 5-HT2A antagonists to reduce psychotic symptoms or as inverse agonists[4][5] 5-HT2C agonists (e.g., lorcaserin) decrease appetite and weight[3]

03

Biological functions

Signal transductionExcitatory neurotransmissionRegulation of mood, cognition, perception, and behaviorModulation of sleep, appetite, and endocrine secretionRegulation of vascular tone and platelet aggregationModulation of learning, memory, and emotional responseOther (complex behavior modulation via protein complexes[3])
04

Disease associations

Neuropsychiatric disease (depression, schizophrenia, bipolar disorder, OCD, addiction)ObesityCardiovascular diseaseSleep disordersPrader–Willi syndrome (for 5-HT2C)[2]Other (associated with impulsivity, anxiety, psychosis and substance use disorders[3])
05

Safety considerations

Hallucinations and altered perception (with agonist drugs, especially psychedelics)Cardiovascular effects (via vascular smooth muscle 5-HT2A activation)Increased suicidality, depression, or behavioral changes (linked to abnormal 5-HT2A upregulation)Weight gain/metabolic syndrome (with antipsychotics)Risk of serotonin syndrome when combined with other serotonergic drugs[1][4][5]Abuse potential with psychedelics and designer drugs targeting these receptors
06

Interacting drugs

Antipsychotics (e.g., clozapine, risperidone, quetiapine)

7 more in the full profile.

07

Biomarkers

5-HT2A receptor density in CNS (can be visualized with PET ligands such as ^18F-FECIMBI-36, Cimbi-36)HTR2A and HTR2C gene polymorphisms (predisposition to psychiatric/obesity phenotypes)[2][3]Receptor mRNA expression levels (diagnostic or research use)

Beyond the preview

Go deeper on Serotonin receptor 2A (5-HT2A) and Serotonin receptor 2C (5-HT2C) (5-HT2A and 5-HT2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serotonin receptor 2A (5-HT2A) and Serotonin receptor 2C (5-HT2C) (5-HT2A and 5-HT2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call